# Exenatide (Byetta) for type 2 diabetes.

> PubMed lists PMID 15933616 in The Medical letter on drugs and therapeutics as Journal Article, with publication-date metadata of 2005-06-06 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15933616-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15933616-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-15933616-exenatide-v1.json
- Content SHA-256: `cc7524faffa914ff85dc455733e73aebe03114336daab0d1a375ba5f5bbedaf0`

## Claims and source pins

### Headline

Exenatide (Byetta) for type 2 diabetes. ([`pubmed-observation-pmid-15933616-2018-12-01-6048229a271c`](#source-pubmed-observation-pmid-15933616-2018-12-01-6048229a271c))

### Summary

PubMed lists PMID 15933616 in The Medical letter on drugs and therapeutics as Journal Article, with publication-date metadata of 2005-06-06 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15933616-2018-12-01-6048229a271c`](#source-pubmed-observation-pmid-15933616-2018-12-01-6048229a271c))

### Paragraph 1

PubMed lists PMID 15933616 in The Medical letter on drugs and therapeutics as Journal Article, with publication-date metadata of 2005-06-06 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15933616-2018-12-01-6048229a271c`](#source-pubmed-observation-pmid-15933616-2018-12-01-6048229a271c))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15933616-2018-12-01-6048229a271c`](#source-pubmed-observation-pmid-15933616-2018-12-01-6048229a271c))

## Sources

<a id="source-pubmed-observation-pmid-15933616-2018-12-01-6048229a271c"></a>
- **Exenatide (Byetta) for type 2 diabetes. · retained source version 1:2018-12-01:current:6048229a271c7fd1e3b2b62dbf6eef74b4edc308001d96c8891ffea7d1b572b1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15933616/) (`pubmed-observation-pmid-15933616-2018-12-01-6048229a271c`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Exenatide (Byetta) for type 2 diabetes." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-15933616-exenatide-v1.json SHA-256: cc7524faffa914ff85dc455733e73aebe03114336daab0d1a375ba5f5bbedaf0.